Semnur Pharmaceuticals, Inc.(SMNR.US)

Semnur Pharmaceuticals, Inc. | 10-Q: FY2025 Q3 Revenue: USD 0

DENALI CAPITAL ACQUISITION CORP | 10-Q: FY2025 Q2 EPS: USD -0.15

Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination | DECA Stock News

Denali Capital Acquisition Corp. (NASDAQ:DECA) announced that shareholders approved an extension of the deadline to complete its initial business combination from April 11, 2025, to December 11, 2025. The extension allows for monthly extensions up to eight times. The company also deposited $874.78 into its trust account, funded by a convertible promissory note from Scilex Holding Company. A Current Report on Form 8-K will be filed with the SEC detailing the voting results.

Denali Capital Acquisition Corp. Announces Adjournment of Extraordinary General Meeting of Shareholders to April 11, 2025 at 10:00 AM ET.

Denali Capital Acquisition Corp. has adjourned its Extraordinary General Meeting of Shareholders to April 11, 2025, at 10:00 AM ET, to allow shareholders more time to consider the proposals. The meeting was initially convened on April 10, 2025. Only shareholders of record as of March 24, 2025, are eligible to vote. Proxies submitted will remain valid unless revoked. Denali Capital is a blank check company focused on business combinations.

Denali Capital Acquisition Pushes Merger Deadline With Extra Funding

Denali Capital Acquisition said Tuesday it has moved its business combination deadline to April 11 and has placed $15,063 into its trust fund. The extension was backed by a zero-interest note from Scilex Holding , which allows Denali to borrow $180,000, repayable upon either a completed deal or liquidation, and convertible into class A shares at $10 per share, the company said. Denali said the remaining balance of $59,545 under the note can be used to fund another monthly extensions if needed.